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Abstract
Attenuated innate immune responses to the intestinal microbiota have been linked to the
pathogenesis of Crohn’s disease (CD). Recent genetic studies have revealed that hypofunctional
mutations of NLRP3, a member of the NOD-like receptor (NLR) superfamily, are associated with
an increased risk of developing CD. NLRP3 is a key component of the inflammasome, an
intracellular danger sensor of the innate immune system. When activated, the inflammasome
triggers caspase-1-dependent processing of inflammatory mediators, such as IL-1β and IL-18. In
the current study we sought to assess the role of the NLRP3 inflammasome in the maintenance of
intestinal homeostasis through its regulation of innate protective processes. To investigate this
role, Nlrp3−/− and wild-type (WT) mice were assessed in the DSS- and TNBS-models of
experimental colitis. Nlrp3−/− mice were found to be more susceptible to experimental colitis, an
observation that was associated with reduced IL-1β reduced anti-inflammatory cytokine IL-10,
and reduced protective growth factor TGF-β. Macrophages isolated from Nlrp3−/− mice failed to
respond to bacterial muramyl dipeptide. Furthermore, Nlrp3-deficient neutrophils exhibited
reduced chemotaxis and enhanced spontaneous apoptosis, but no change in oxidative burst. Lastly,
Nlrp3−/− mice displayed altered colonic β-defensin expression, reduced colonic antimicrobial
secretions and a unique intestinal microbiota. Our data confirm an essential role for the NLRP3
inflammasome in the regulation of intestinal homeostasis and provide biological insight into
disease mechanisms associated with increased risk of CD in individuals with NLRP3 mutations.
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Introduction
The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD)
are immunological disorders characterized by chronic and relapsing inflammation. Although
the exact etiology of IBD has yet to be elucidated, the current paradigm suggests that the
chronic mucosal inflammation is driven by aberrant interactions between the mucosal
immune system and luminal antigens in genetically susceptible individuals (1). Genome-
wide association (GWA) studies have revealed a number of candidate genes that are
associated with an increased risk of developing IBD.
One of the best characterized IBD susceptibility genes is NOD2/CARD15. Mutations in
NOD2, an intracellular receptor of the innate immune system belonging to the NLR
(nucleotide binding domain leucine-rich-repeat gene-containing) family of proteins, are well
established to be associated with an increased risk for the development of CD (1). Such
mutations confer hyporesponsiveness to bacterial antigens, suggesting that the initiation of
chronic inflammation may involve an inability of the innate immune system to respond
appropriately to the presence of intracellular bacteria (2,3). Indeed, monocytes from CD
patients with disease-associated NOD2 mutations produce less mature IL-1β in response to
microbial muramyl dipeptide (MDP), a peptidoglycan component of gram-positive and
gram-negative bacteria (4). Interestingly, this profound decrease in IL-1β secretion was
associated with an induction of IL-1β mRNA suggesting an overlying defect in NOD2-
mediated IL-1β processing. NOD2 mutations are also associated with alterations in the
intestinal microbiota, an effect that has been linked to reduced antimicrobial secretions from
the intestinal epithelium (5,6). These data highlight the importance of the innate immune
system in the maintenance of intestinal homeostasis. The promotion of barrier function and
the efficient elimination of invading bacteria are two key innate immune processes that are
necessary in preventing chronic activation of the mucosal immune system, a hallmark of
IBD.
Recently, the NLRP sub-family of the NLR family of proteins, distinguished from the other
NLRs by an N-terminal pyrin domain, has been implicated in the pathogenesis of chronic
inflammatory conditions (7,8). The best characterized member of the NLRP sub-family is
NLRP3, a close relative of NOD2, which has been shown to trigger IL-1β and IL-18
processing and release in response to a variety of pathogen and endogenous danger signals
including monosodium urate crystals (MSU), adenosine triphospate (ATP), silica and
asbestos (9-11). Activation of NLRP3 leads to recruitment of the adaptor protein ASC and
of pro-caspase-1 to form a multiprotein complex termed the inflammasome. Inflammasome
activation triggers the caspase-1-dependent processing of inflammatory molecules pro-IL-1β
and pro-IL-18, allowing for the secretion of the mature forms of these cytokines (12).
Hyperfunctional mutations in NLRP3 confer increased IL-1β processing and are associated
with diffuse inflammatory conditions collectively termed cryopryin-associated periodic
syndromes (CAPS) (13). In contrast to the mutations in CAPS that enhance NLRP3-
dependent IL-1β release, GWA studies have found that polymorphisms conferring a
hypofunctional NLRP3 phenotype are associated with CD (14,15), a scenario reminiscent of
the NOD2 paradigm. In these studies, monocytes isolated from patients who were
homozygous for the risk allele displayed reduced IL-1β release in response to NLRP3
activation.
Recent studies assessing the role of the inflammasome in models of experimental intestinal
inflammation have revealed that mice deficient in Nlrp3, ASC or caspase-1 exhibit enhanced
susceptibility to dextran sulphate sodium (DSS) and 2,4,6-trinitrobenzenesulfonic acid
(TNBS). Zaki et al. (2010) reported that Nlrp3−/− mice exhibited severe transmural
inflammation following oral DSS treatment, a phenotype that was dependent on Nlrp3-
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deficiency in non-bone-marrow-derived tissues (16). Dupaul-Chicoine et al. (2010) also
found that loss of Nlrp3 resulted in more severe DSS colitis and again it appeared that this
was dependent on non-bone marrow derived tissues (17). They also found that it appeared
that the increase in colitis severity was due to the impaired IL-18 processing and that the
phenotype could be partially reversed with exogenous IL-18 (17). Allen et al. (2010) also
found that loss of Nlrp3 resulted in increased DSS-induced intestinal injury and
inflammation but their chimeric studies found that the increased disease severity was
dependent on the loss of Nlrp3 in bone-marrow-derived cells (18). In complete contrast to
the aforementioned studies, Bauer et al. (2010) recently reported that the loss of Nlrp3 or
caspase-1 was protective in the DSS model of colitis and that in vivo inhibition of caspase-1
attenuated DSS-induced inflammation (19).
Given the contrasting data published regarding the mechanism through which the
inflammasome regulates intestinal homeostasis, we sought to explore other mechanisms
through which NLRP3 may function in the gastrointestinal tract. Our data confirm that
Nlrp3−/− mice are markedly more susceptible to experimental colitis compared to their WT
counterparts, displaying decreased expression of TGF-β and IL-10, and possessing
significant defects in macrophage and neutrophil function. In addition, Nlrp3−/− mice had
altered colonic β-defensin expression, reduced crypt bactericidal capacity and marked
changes in the intestinal microbiota. Our data clearly shows that the NLRP3 inflammasome
plays a broad role in the innate intestinal immune response and maintenance of intestinal
homeostasis.
Material and Methods
Animals
Wild-type (WT, C57Bl/6 background) and Nlrp3−/− (C57Bl/6 background) mice were
generated from Nlrp3+/- mice (a gift from Dr. Jurg Tschopp, University of Lausanne,
Dorigny, Switzerland) and used between 8-10 weeks of age. All experiments involving
animals were approved by the Animal Care Committee, University of Calgary.
Induction and assessment of colitis
Colitis was induced by the addition of dextran sulphate sodium (DSS, 2.5% wt/vol,
molecular weight, 40,000; ICN Biomedical, Aurora, OH) added to the drinking water as we
have described previously (20,21). Animals were assessed daily and mean body weights
were recorded. DSS consumption was equal between groups. Mice were sacrificed at day 7
of DSS exposure. Hematocrit values were assessed as an index of blood loss and serum was
collected for assessment nitric oxide levels. The entire colon was removed, opened along the
mesenteric border and fecal material removed. Segments of tissue were flash frozen for
assessment of tissue cytokine levels and myeloperoxidase (MPO) levels, an indicator of
colonic granulocyte infiltration. Additional segments were fixed in 10% neutral-buffered
formalin, embedded in paraffin, sectioned, and stained with H&E in standard fashion. The
severity of colitis was scored histologically using 2 different parameters on coded slides in a
blinded fashion. An inflammation score was used: 0, no inflammation; 1, increased
inflammatory cells noted above the muscularis mucosa only; 2, increased inflammatory cells
involving the submucosa and above; 3, increased inflammatory cells involving the
muscularis and/or serosa (20). The extent of ulceration was determined by measuring the
amount of ulceration on each section as measured along the muscularis mucosa (expressed
as percentage ulcerated mucosa) (20). Following our studies in the DSS model, we assessed
whether the increased susceptibility observed in Nlrp3−/− mice, occurred in another murine
model of colitis. The TNBS (2,4,6-trinitrobenzenesulfonic acid) model of colitis was used
with some modifications on our initial description of this model (22). Mice were given a
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rectal administration of 100 μL TNBS (Sigma-Aldrich Ltd. catalogue No. 92823, Ontario,
Canada) (30 mg/mL) in 20% EtOH. A 5F infant feeding tube catheter with side ports
(Mallinckrodt Inc., St. Louis, MO; catalogue No. 85771) was inserted 2.5 cm (measured
from the midway point between the 2 catheter side ports) up the colon, and the 100 μL of
solution was slowly administered over 30 seconds while pressure was applied to the rectal
area to prevent leakage. The tube was slowly removed, and the rectal pressure was
maintained for a further 30 seconds. All animals were killed 3 days following administration
of TNBS/EtOH. The severity of colitis was assessed by monitoring changes in body weight
and inflammation via assessment of colonic myeloperoxidase levels. Histological
assessment was performed in a blinded fashion using the following criteria: Inflammation
score: 0, normal; 1, increased inflammatory cells in lamina propria; 2, increased
inflammatory cells in submucosa; 3, dense inflammatory cell mass; 4, transmural
inflammation. Epithelial damage score: 0, nil; 1, patchy loss of epithelium; 2, widespread
loss of epithelium; 3, complete absence of epithelium with loss of normal colonic
architecture (20).
Tissue myeloperoxidase assay
MPO activity was determined following a published protocol (23). Briefly, tissue samples
were weighed and suspended in 50 mmol/L potassium phosphate buffer (pH 6.0) containing
5 mg/ml hexadecyltrimethylammonium bromide (Sigma Chemical Co.) at a ratio of 50 mg
tissue to 1 ml of buffer. Tissues were homogenized by a polytron tissue homogenizer for 15
seconds, and 1 ml was decanted into sterile Eppendorf tubes and centrifuged at 12,000 rpm
for 15 minutes. Using a microtiter plate scanner, 200 μl of the reaction mixture (containing
16.7 mg of o-dianisidine (Sigma Chemical Co.), 90 ml of distilled H2O, 10 ml of potassium-
phosphate buffer, and 50 μl of 1% H2O2) was added to each well containing 7 μl of sample
in a standard 96-well plate and three absorbance readings at 30-second intervals at 450 nm
were recorded. MPO activity was measured in units/mg tissue, where one unit of MPO was
defined as the amount needed to degrade 1 μmol of H2O2 per minute at room temperature.
Assessment of tissue cytokine levels
Colonic segments stored at −80°C were placed in ice-cold lysis buffer (250 μl/25 mg tissue;
10 mM Tris pH 7.5, 1% NP-40, 150 mM NaCl, and protease inhibitor cocktail) and minced
with dissection scissors. Tissues were then homogenized by a polytron tissue homogenizer
for 15 seconds and 1 ml was decanted into sterile Eppendorf tubes and centrifuged at 12,000
rpm for 15 minutes. The supernatant was then filtered through an Ultrafree-MC centrifugal
filter device (Millipore Corp.) with centrifugation at 12,000 for 5 minutes. The protein
concentration of the filtrate was assessed using Biorad Protein Assay reagent (Biorad) and
all samples were equalized for protein concentration by dilution with lysis buffer. Cytokine
levels were assessed using a Luminex XMap bead-based cytokine array according to the
manufacturer’s instructions (Luminex Corp). Briefly, pre-labeled beads were mixed and
added to each well. Samples were prepared in triplicate at two different total protein
concentrations (10 and 35 mg total protein) and added to their respective wells. Samples
were incubated with beads for 2 hours and then washed 3 times and incubated with
secondary antibodies for 1 hour. Following incubation, wells were washed and then beads
assessed in the Luminex 200 System. Mean fluorescence values were measured and
cytokine concentrations calculated using the prepared standards.
Assessment of serum nitrates/nitrates
To assess NOx production during DSS-induced colitis, nitrate and nitrite in the plasma of
both WT and Nlrp3−/− mice were assayed as described previously (20). A modified Greiss
reaction kit (Bioxytech NO-540; Oxis Research, Montreal, QC, Canada) was used per the
manufacturer’s guidelines. An aliquot of 160 μl of plasma was added to 640 μl of 1%
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ZnSO4 followed by the addition of 800 μl of 55 mM NaOH; samples were then vortexed
and centrifuged at 10,000 g for 10 minutes. Supernatant (1,000 μl) was added to the assay
buffer, incubated for 20 minutes at room temperature, recentrifuged at 10,000 g for 30 s, and
then incubated with the final reaction solutions for 20 minutes at room temperature, and
absorbance was then measured at 540 nm. The absorbance was plotted against standards and
fit with linear regression, followed by calculation of NOx according to the manufacturer’s
recommendations.
Isolation of mouse macrophages
Mouse peritoneal macrophages were obtained by injecting mice with a 4% thioglycollate
(BD-Biosciences) PBS solution for 72 hours before harvesting macrophages through
peritoneal lavage. Macrophages were plated in complete RPMI media overnight and
stimulated with 10 ng/mL of ultra-pure LPS (Invivogen) for 30 minutes prior to treatment.
Cells were treated with muramyl dipeptide (MDP, 10μg/mL, Invivogen), monosodium urate
crystals (MSU, 50μg/mL, Sigma-Aldrich), aluminum adjuvant (Alum, 500μg/mL, Sigma-
Aldrich) and ATP (5 mM, Sigma-Aldrich) for 6 hours. Following treatment, culture
supernatants were harvested and inflammasome activation was detected through Western
blot analysis of IL-1β (RD Systems) in culture supernatants.
Isolation of mouse bone marrow-derived neutrophils
Neutrophils were isolated from the bone marrow of WT and Nlrp3−\− mice as described by
Lieber et al. (2004) (24). Briefly, femurs and tibias of the mice were dissected, the marrow
flushed with phosphate buffered saline (PBS, PH=7.4) then centrifuged at 1300 rpm for 6
minutes at 4 °C. The marrow was layered on a 3-step Percoll (Amersham Bioscience)
gradient (72 %, 64 %, and 52 %), and centrifuged at 2600 rpm for 30 minutes at 4 °C.
Neutrophils were taken from the layer between the 64 % and 72 % Percoll and washed once
with PBS and suspended in RPMI culture media plus 20 % fetal bovine serum (FBS)
(GIBCO) at a concentration of 1.0 × 107 cells/ml.
In vitro under-agarose gel assay for neutrophil chemotaxis
The under-agarose assay was performed as described in detail by Heit et al. (2002) (25). In
brief, Falcon 35 mm × 10 mm culture dishes were filled with 3 ml of a 1.2 % agarose
solution. Three wells were created in the gel 2.5 mm apart in a horizontal line. Neutrophil
chemotaxis towards KC (R&D Systems; 1.25μM), LTB4 (Calbiochem; 1μM), C5a
(Calbiochem; 1μM), or WKYMVm; fMLP peptide (Phoenix Pharmaceuticals; 1μM) was
determined by loading the center well with 10 μl of the chemoattractant and the outer wells
with 10 μl of WT and Nlrp3−\− neutrophils (1 × 107 cells/ml). Control conditions were
performed in the same experiments by adding 10 μl of PBS in the center well instead of the
chemoattractant. Once loaded, the gels were incubated for 4 hours in a 37°C/5% CO2
incubator, which allowed sufficient time for neutrophils to migrate the entire distance
between the wells. The results were recorded by using a video camera attached to a ZEISS
Axiovert 135 microscope for subsequent analysis. Neutrophil chemotaxis was determined by
subtracting the number of cells which migrated toward the source of chemoattractant minus
the number of cells which migrated in the opposite direction and expressed as a percentage
of the total number of cells that migrated in either direction.
Assessment of spontaneous neutrophil apoptosis
Freshly isolated bone-marrow derived neutrophils were resuspended in RPMI culture media
plus 20% FBS and plated in Falcon 35 mm × 10 mm culture dishes at a density of 1 × 106
cell/mL (6 separate dishes per animal). Once seeded, cells were incubated for 12 hours in a
37°C/5% CO2 incubator. Following the incubation period, cells were stained for flow
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cytometry to assess viability (7-AAD) and early apoptosis (Annexin-V) using the PE
Annexin V Apoptosis Detection Kit I as per the manufacturer’s instructions (BD
Pharmingen). The 6 dishes per animal were stained in the following manner: 1: cells only
(negative control), 2: cells stained with 7-AAD alone, 3: cells stained with Annexin-V-PE,
4-6: cells stained with 7-ADD and Annexin-V-PE (26,27).
Assessment of neutrophil superoxide production
To assess the function of Nlrp3-deficient neutrophils we assessed superoxide generation by
measuring the reduction of cytochrome c as described previously (28). Briefly, reactions
were prepared with cytochrome c (200 μM) and bone-marrow-derived neutrophils (5 × 105
cells). In some assays, superoxide dismutase (SOD, 1500 U) was included to quench
superoxide accumulation. The reaction was initiated by stimulation with PMA (8 μM) or
fMLP (8 mM). The reaction mixtures were mixed and incubated at 37 °C for 25 min,
followed by harvesting of supernatant by centrifugation at 900 × g for 20 min at 4 °C.
Reduced cytochrome c in the cell free supernatant was measured at 550 nm on a double
beam spectrophotometer.
Terminal Restriction Fragment Polymorphism (TRFLP) Analysis
Wild-type mice were derived from littermates of the Nlrp3+/- heterozygotes that were used
to establish the Nlrp3−/− line. Both animal lines were continuously housed in the same
animal care facility, on the same animal rack, and received the same food and water. All
samples were taken from female mice at 8 weeks of age. Gentle handling of the mice evoked
passage of fecal pellets, which were immediately collected and stored at −70°C. Total DNA
was then extracted from 2-3 fecal pellets (20-30 mg) from each mouse using the QIAamp
DNA Stool Mini Kit (Qiagen, Mississauga, ON, Canada). The process was modified to
ensure uniform bacterial DNA extraction by the addition of a 2 minute mechanical bead (0.1
mm zirconia:silica) beating step (29). PCR was performed with primers 8f (5′-
AGAGTTTGATCCTGGCTCAG-3′) labelled with 6-FAM and 926r (5′-
CCGTCAATTCCTTTRAGTTT-3′) which target part of the bacterial 16S rRNA gene (30).
Standard PCR conditions were used: 94 °C for 2 minutes, 25 cycles of 94 °C for 1 minute,
56 °C for 1 minute, 72 °C for 1 minute, and a final extension at 72 °C for 10 minutes. Three
independent PCR amplifications were performed on each stool sample and the products
were pooled and purified using the QIAquick PCR Purification Kit (Qiagen). For terminal
restriction fragment length polymorphism analyses (TRFLP), five μL of each pooled,
purified PCR product was digested overnight at 37 °C with 10 U of HpaII (Invitrogen,
Burlington, ON, Canada) and again purified. Approximately 5 ng of digested sample was
injected into an ABI 3730XL Genetic Analyzer (University of Calgary, Core DNA Services)
and fragment analysis was performed using the GeneMapper software package (ABI
Biosystems, Streetsville, ON, Canada) and LIZ1200 (ABI Biosystems) as a size standard.
Binning was performed at 1 bp and only peaks with a minimum peak threshold of 50
fluorescence units were included.
RNA isolation and qPCR analysis
Mouse colonic sections were removed and placed directly in Trizol and flash-frozen. Total
RNA was extracted from biopsies and isolated cells populations using the Trizol method
according to the manufacturer’s instructions (Invitrogen). To quantify changes in gene
expression an ABI 7500 real-time PCR thermocycler was used to survey mRNA levels. All
RNA samples were reversed transcribed to cDNA using the RT2 First-strand kit
(SABiosciences). All primers were purchased from SABiosciences. PCR reactions were
composed of primers, cDNA and RT2 real-time SYBR Green/Rox PCR master mix.
Amplification plots were examined with the accompanying Sequence Detection Software to
determine the threshold cycle (Ct). In all reactions endogenous control (GAPDH) was
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amplified, and the Ct was determined. Data are expressed a fold-change calculated using the
ΔΔCt method (31).
Colonic crypt killing assay
The antimicrobial capacity of colonic crypt secretions was performed as described
previously (32), with minor modifications. Colonic crypts were isolated from the naïve WT
and Nlrp3−/− mice, resuspended in iPIPES buffer (10 mM PIPES; pH 7.4 and 137 mM
NaCl) and counted. For experiments, 1000 crypts were incubated in 40 μL of iPIPES buffer
at 37 °C for 30 min. Following this period, 10 μL of a crypt-free isolate was added to 104 E.
coli (DH5α) in 200 μL of LB broth and incubated for 37 °C for 60 min. The antimicrobial
capacity of crypt-culture extracts was assessed by counting the overnight growth of WT and
Nlrp3−/− crypt-treated E. coli, and expressed as a percentage of the growth observed in
untreated E. coli cultures.
Statistical Analysis
Data are presented as the mean ± standard error of the mean (SEM). Parametric data were
analyzed using a 1-way ANOVA followed by a Dunnett Multiple Comparisons post-test.
Nonparametric data (scoring) were analyzed using a Kruskal–Wallis test (nonparametric
ANOVA) followed by a Dunn Multiple Comparisons post-test. An associated probability (P
value) of <0.05 was considered significant. All statistical analysis was performed with
Graph Pad Instat and Prism 3.0 programs (GraphPad, San Diego, CA).
TRFLP data were tabulated and analyzed by principal component analysis using SIMCA-P
(v11.5) multivariate statistics software (Umetrics, Umeå, Sweden) to identify intrinsic
clusters within our dataset and the key bacterial phylotypes that determine such clustering.
Orthogonal-projection to latent structure-discriminant analysis (O-PLS-DA) was carried on
TRFLP binary data (i.e. peak presence or absence) using unit variance scaling. OPL-S
coefficients were used to visualize the major variables contributing to the discrimination in
the model. The model was subject to 7-fold cross validation, an iterative process whereby
one-seventh of the samples were excluded and used to predict fit into the modified model.
The Q2 value represents how accurately the model predicts the dataset.
On this basis of OPL-S coefficients, several terminal restriction fragments (TRFs) were
identified as the main factors driving the discriminant model. These TRFs were then used to
identify major bacterial phylotypes that distinguished wild type and NLRP3 knock out mice.
A virtual digest (ISPaR) with HpaII and primers 8f-926r of the HQ database (containing
only mammalian gut bacterial 16S rRNA gene sequences) on the MiCA website (Microbial
Community Analysis, version 3, Department of Biological Sciences, University of Idaho,
http://mica.ibest.uidaho.edu/) was performed to generate a list of accession numbers for each
terminal restriction fragment (TRF). This list was uploaded to SEQCART on the Ribosomal
Database Project website (http://rdp.cme.msu.edu/) and a reference library was created (33).
The TRFs of interest were compared to this reference library and a list of putative gut
microbes comprising each profile was generated. Only TRFs that had 100% identity with
predicted TRFs at the phylum level were matched to their respective accession numbers.
Results
Nlrp3−/− mice are more susceptible to experimental colitis
Throughout the course of DSS exposure, Nlrp3−/− mice exhibited significantly greater
weight loss (Fig.1A) than their WT counterparts. Furthermore, Nlrp3−/− mice displayed
significantly lower hematocrits, indicative of increased fecal blood loss (Fig.1B), higher
MPO levels (Fig.1C) and more severe injury and inflammation upon histological assessment
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(Fig.1D-E). As observed with DSS, Nlrp3−/− mice were more susceptible to TNBS as
indicated by significantly greater weight loss (Fig.2A), elevated colonic MPO (Fig.2B),
enhanced inflammation and tissue damage (Fig.2C-D).
The profiles of inflammatory mediators are altered in Nlrp3−/− mice exposed to DSS
The role NLRP3 inflammasome plays a key role in the processing of IL-1β. As expected, the
Nlrp3−/− had lower levels of IL-1β during DSS colitis (Fig.3A). Increased NOx was noted in
the Nlrp3−/− mice (Fig.3B). Strikingly, at day-7 of DSS exposure, the Nlrp3−/− mice had
significantly lower levels of the protective molecules IL-10 and TGF-β compared to WT
(Fig.3C-D). Interestingly, Nlrp3−/− mice had decreased colonic tissue levels of the
chemokines IP-10 and KC (Fig.3E-F). No significant changes were noted in MIP-1α and
MIP-2 (see Supplementary Fig.1).
Nlrp3-deficient macrophages lack functional responses to bacterial muramyl dipeptide
Given that monocytes isolated from patients with CD-associated NOD2 mutations fail to
respond to bacterial products (34,35), we sought to assess whether the loss of NLRP3 would
alter the response to bacterial muramyl dipeptide, a potent NLR activator. Pretreatment of
mouse peritoneal macrophages, both WT and Nlrp3−/− cells, with ultra-pure LPS triggers
the production of pro-IL-1β through a TLR-4-dependent pathway (36). Subsequent exposure
of WT macrophages to MDP triggered the processing and release of the mature IL-1β into
the culture supernatant, which was abolished by glyburide, a purported selective inhibitor of
the NLRP3-inflammasome(37) (Fig.4A). MDP-induced IL-1β processing and release was
absent in macrophages isolated from Nlrp3−/− mice (Fig.4B). Standard inflammasome
activators MSU, Alum and ATP induced IL-1β processing which was blocked by the
NLRP3 inhibitor, glyburide, and was absent in Nlrp3−/− macrophages (Fig.4A-B).
Nlrp3-deficient neutrophils exhibit impaired chemotaxis and enhanced spontaneous
apoptosis
Neutrophils play a key role in the innate immune response within the intestinal mucosa (38).
Patients with Muckle-Wells syndrome (a multisystem inflammatory disease, due to a
mutation of NLRP3) have defects in neutrophil chemotaxis (39). Using the under-agarose
assay to assess neutrophil movement, it was revealed that bone-marrow-derived Nlrp3−/−
neutrophils displayed significantly increased chemokinesis (i.e. non-directional chemokine
induced movement) (Fig.5A), but significantly reduced chemotaxis towards KC, WKTMVm
and C5a (Fig.5B). Altered caspase-1 signaling can also impact neutrophil survival (40).
Consistent with this we found that bone-marrow-derived neutrophils isolated from Nlrp3−/−
mice exhibited significantly greater levels of spontaneous apoptosis (Fig.5C). To further
assess neutrophil function we measured superoxide production in response to PMA and
fMLP stimulation. PMA-induced superoxide production was no different in Nlrp3-deficient
neutrophils when compared to WT cells (Fig.5D). fMLP stimulated Nlrp3-deficient
neutrophils produced similar overall superoxide levels, but exhibited reduced production at
early time-points (Fig.5E).
Nlrp3-deficient mice exhibit altered colonic β-defensin expression and decreased
antimicrobial capacity
NLR signaling has been linked to the regulation of Paneth cell function and the release of
antimicrobial compounds terms defensins (5,41). Reduced defensin expression has been
associated with CD patients expressing hypofunctional NOD2 mutations (5,41). Given the
colonic nature of the injury observed in our model, we sought to assess the expression of
select colonic β-defensins in Nlrp3−/− mice. Marked changes in β-defensin transcript
expression were observed in both naïve and DSS-treated animals (Fig.6A-B). Naïve
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Nlrp3−/− mice produced similar levels of defb2/MBD-2, defb3/MBD-3 and defb4/MBD-4,
but markedly higher levels of defb1/MBD-1. At day-7 DSS, Nlrp3−/− mice had reduced
expression of defb1/MBD-1 and defb4/MBD-4, but increased expression of defb3/MBD-3
compared to WT (Fig.6A-B). Alterations in defensin expression were associated with a
reduction in the antimicrobial capacity of Nlrp3−/− crypt secretions when assessed in a
bacterial killing assay (Fig.6C).
The intestinal microbiota is altered in Nlrp3−/− mice
Considerable attention has been paid to the role of the intestinal microbiota in the
maintenance of intestinal homeostasis. Effective microbial clearance by the innate immune
system and the release of protective antimicrobial secretions from the intestinal epithelium
are thought to protect the mucosa from microbial insult and prevent inappropriate activation
of the resident cells in the LP (1). Dysbiosis has been observed in IBD patients (42,43) and
recently it has been shown that loss of NOD2 results in an altered intestinal microbiota in
mice (44). Thus we sought to assess the microbiota in Nlrp3−/− mice. Although the WT
mice used in these studies were derived from littermates of the Nlrp3−/− mice and
continuously housed in the identical animal care facilities, their intestinal microbiota
displayed marked differences. Supervised OPL-S discriminant analysis readily distinguished
WT and Nlrp3−/− mice on the basis of fecal microbiota (Fig.6D). The Q2 value of this model
was excellent at 0.77; fecal TRFLP profiles were able to classify the two groups according
to genotype with a reliable 77% accuracy. OPL-S coefficients revealed several TRFs that
were significantly more common in WT animals and several TRFs that were significantly
more common in Nlrp3−/− mice (Fig.6E). We were able to identify 6 bacterial genera in WT
mice and 10 bacterial genera in Nlrp3−/− mice that differentiated these two lines at a 100%
confidence level (Table 1). Of interest, in Nlrp3−/− mice, we detected potentially pathogenic
members of Enterobacteriaceae, which at the genus level could match various species of
Citrobacter, Proteus or Shigella. Also, the genus Mycobacterium was uniquely found in
Nlrp3−/− mice, as were Collinsella, Subdoligranulum, Clostridium and Ralstonia.
Discussion
We confirm that Nlrp3-deficiency confers an enhanced susceptibility in two different
experimental models of colitis. This NLRP3 paradigm appears reminiscent of the CD-
related, hypofunctional mutations of NOD2 that have been found to impair responsiveness
to microbial products and may regulate the intestinal microbiota (4,44,45). The parallels are
even more intriguing since NOD2 and NLRP3 are members of the same NLR superfamily.
Activation of the NLRP3 inflammasome by danger- and/or pattern-associated molecular
patterns results in caspase-1-dependent processing of the inflammatory cytokines IL-1β and
IL-18 (12). Although hyperfunctional mutations of NLRP3 have been associated with
several inflammatory conditions in humans, it is the hypofunctional mutations that are
associated with an increased risk of CD. This is clearly supported by our data and others,
which indicate that the loss of NLRP3 function results in an increased susceptibility to
experimental colitis (16-18).
Interestingly, mice deficient in components of the innate immune system, including TLR
family members and the downstream signaling molecule MyD88, also display enhanced
susceptibility to chemically-induced colitis (46-49), suggesting that reduced microbial
sensing may contribute to the initiation and perpetuation of intestinal inflammation. This is
supported by observations that resistance to DSS- and TNBS-induced colitis can be
conferred by strategies that enhance signaling through the innate immune system (i.e. MDP
pretreatment) (50,51).
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During assessment of the colonic cytokine/chemokine profiles following the 7-day DSS
exposure, we observed striking differences between the WT and Nlrp3−/− mice. Nlrp3−/−
mice exhibit a reduction in colonic IL-1β during intestinal inflammation. Furthermore,
macrophages isolated from Nlrp3−/− mice failed to process and release IL-1β in response to
MDP. Although these data appear paradoxical, given the pro-inflammatory role for IL-1β in
many inflammatory conditions, the observation parallels the hyporesponsiveness and
reduced IL-1β release observed in monocytes isolated from patients with Crohn’s-associated
NOD2 mutations (3,35).
The increased severity of colitis in the Nlrp3−/− mice was associated with higher levels of
NOx and reduced expression of the anti-inflammatory cytokine IL-10 and the protective
growth factor TGF-β. The associated higher levels of NOx in the Nlrp3−/− mice confirm
previous work showing that NO plays a damaging or proinflammatory role in DSS colitis,
an effect mediated by iNOS (20,52). The increased inflammation in the presence of
decreased IL-10 and TGF-β was not unexpected given that previous studies have shown that
targeted deletion of these protective mediators, or blockade of downstream signaling, leads
an increased susceptibility to experimental colitis and the induction of spontaneous colitis
(53,54). However, little is known about the NLRP3 inflammasome-dependent regulation of
these cytokines.
Although the Nlrp3−/− mice had more severe colonic inflammation in response to DSS,
there were reduced levels of the potent chemokines KC and IP-10, suggesting that these
mediators are not essential for leukocyte recruitment and inflammation in DSS-induced
colitis. The role of the inflammasome in the regulation of KC is controversial. Double-
stranded RNA, a potent activator of the NLRP3 inflammasome (55), induces KC release in
tissue macrophages (56) and airway tissue following in vivo challenge (57). However,
Griffith et al. (2009) reported that hemozoin, a metabolite of hemoglobin and potent
activator of the NLRP3 inflammasome, could induce inflammation and neutrophil migration
when added to the peritoneal cavity but that MCP-1 and KC production was inflammasome
independent (58).
Recent GWA studies have found that many of the genes associated with IBD encode
components of the innate immune system (1), suggesting that IBD pathogenesis involves an
impaired innate inflammatory response. In this paradigm, a delayed, or aberrant,
inflammatory response to tissue injury or invasion of luminal bacteria fails to be effectively
resolved and chronic inflammation is induced. There are several examples of innate immune
defects resulting in intestinal inflammation, the most common being hypofunctional
mutations of NOD2 in observed in CD patients. Defects resulting in decreased neutrophil
numbers, such as congenital and cyclical neutropenia, and impaired neutrophil trafficking
can result in a CD-like phenotype (38). Impaired leukocyte recruitment and phagocytic
activity has also been described in CD (38). Marks et al. (2006) reported that CD patients
displayed an aberrant innate immune response to tissue injury exhibiting reduced neutrophil
accumulation and decreased expression of IL-8 and IL-1β 6 hours post-injury (59).
Furthermore, CD patients inoculated with E. coli exhibited an attenuated inflammatory
response (59). In keeping with the aforementioned reports, we found that neutrophils
isolated from Nlrp3−/− mice have altered neutrophil migration and apoptosis. Nlrp3-
deficient neutrophils exhibited attenuated chemotactic responses to KC, C5a and fMLP
ligands and enhanced spontaneous apoptosis. However, there were no marked differences in
neutrophil superoxide production in Nlrp3-deficient animals compared to WT mice. Further
studies are required to fully assess the role of Nlrp3 in neutrophil function and how it
impacts intestinal inflammation and homeostasis.
Hirota et al. Page 10
Inflamm Bowel Dis. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The intestinal epithelium plays a key role regulating the mucosal inflammatory status. It has
been postulated that one of the functions of the innate immune system is to drive processes
that contribute to the restitution of the intestinal epithelium following injury. Indeed, Zaki et
al. (2010) reported that deletion of Nlrp3 and caspase-1 reduced the capacity of the intestinal
epithelium to recover following DSS-induced injury (16). Another important function of the
innate immune system within the intestinal mucosa is the regulation and release of
antimicrobial factors such as defensins (60). Interestingly, the NOD2 mutations associated
with CD confer impaired Paneth cell function and attenuated defensin release (5,61). NOD2
and NLRP3, both members of the NLR family of receptors, share common downstream
signaling (i.e. caspase-1-dependent IL-1β processing); however, it is not known if the
NLRP3 inflammasome regulates defensin expression. Zaki et al. (2010) reported that
Nlrp3−/− mice exhibited and enhanced bacteremia following DSS-exposure (16).
Furthermore, Dupaul-Chicoine et al. (2010) reported elevated levels of mucosally-associated
bacteria in DSS-treated caspase-1-/- mice (17). Neither of these observations is surprising
due to the markedly increased DSS-induced injury and inflammation in these animals
compared to wild type mice. However, antibiotic treatment was able to normalize the
Nlrp3−/− phenotype suggesting that the microbiota are integral in the driving the
inflammation observed in these mice (16). Since other NLR’s (e.g. NOD2) clearly regulate
antimicrobial secretions, we hypothesized that the NLRP3 inflammasome may play a more
direct role in regulating the antibacterial properties of the intestinal epithelium. To this end,
we assessed the transcript levels for colonic defensins in Nlrp3-/- animals before and
immediately following a 7-day course of DSS. The murine colon expresses β-defensins and,
to date, 6 have been identified. Mouse β-defensins (MBD)-1 to -4 are the best characterized,
and MBD-2 to -4 are highly inducible during bacterial infection or inflammatory responses
(60). In human studies, the orthologue of MBD-3, human β-defensin 2, is significantly
elevated in IBD patients, whereas human β-defensin 1 (MBD-1) is not changed (62). Our
data reveal dysregulation of β-defensin expression in both naïve and DSS-exposed Nlrp3−/−
mice compared to WT mice. Specifically, naïve Nlrp3−/− mice exhibited enhanced MBD-1
expression compared to WT mice, an effect which is lost upon DSS treatment. In addition to
MBD-1, MBD-4 was also significantly reduced in Nlrp3−/− mice. MBD-2 expression was
not different between naïve and DSS-treated Nlrp3−/− and WT mice, whereas MBD-3 was
significantly elevated in response to DSS treatment. These observations parallel the
upregulation of human β-defensin 2 in IBD patients during mucosal inflammation (62).
Since both human and murine β-defensins are extremely difficult to assess at the protein
level in vivo the above studies as well as our study assessed expression at the mRNA level.
Despite this, we sought to define the general antimicrobial capacity of colonic crypt
secretions using an established colonic crypt killing assay (32). Since Nlrp3-deficiency is
associated with increased mucosal bacteria and systemic bacterial dissemination, we
hypothesized that colonic crypts isolated from Nlrp3−/− mice would exhibit reduced
bacterial killing capacity. Indeed colonic crypt secretions of Nlrp3−/− mice had significantly
less antimicrobial activity when compared to WT mice. These data suggest that a loss in
antimicrobial function, in conjunction with the previously reported failure to resolve
following DSS-induced injury, may contribute to the elevated levels of mucosally-associated
bacteria and the associated mucosal inflammation.
Intestinal dysbiosis has been linked to the etiology of IBD. Dupaul-Chicoine et al. (2010)
reported that Nlrp3−/− mice exhibited greater bacterial loads within colonic isolates (17),
however the composition of the microbiota was not assessed in this report. Thus we sought
to profile the fecal microbiota from naïve Nlrp3−/− mice and their WT littermates.
Remarkably, the fecal microbiota in Nlrp3−/− mice was dramatically different from that in
WT mice which were bred from the same littermates and housed in the same facility, as was
revealed by TRFLP analyses. Host genotype plays an essential role determining the
composition of intestinal microbiota. For instance, loss of MyD88 alters Paneth cell
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function, reducing defensin release and removing selective pressure that could allow
remodelling of the microbiota (63). Similarly, a dysregulated β-defensin system in Nlrp3−/−
mice may be a primary mediator of the dysbiosis observed in these mice. This is supported
by the reduced antimicrobial capacity of secretions derived from crypts isolated from
Nlrp3−/− mice compared to those isolated from WT mice. Interestingly, the observed
microbial shifts were present in Nlrp3−/− mice prior to the induction of colitis, suggesting
that bacterial dysbiosis may play a role in the increased susceptibility of these animals to
experimental colitis. Dysbiosis has also been reported in mice deficient in another of the
NLR family, NOD2 (44). This supports the theory that dysbiosis plays a predisposing role in
the development of IBD in humans (64).
In summary, our studies indicate that loss of NLRP3 results in changes within several
aspects of the innate immune system, and may directly influence the intestinal microbiota.
Specifically, we confirm reports that Nlrp3−/− mice display enhanced susceptibly to
experimental colitis (16-18). Moreover, our data also demonstrate alternative mechanisms
that may explain the findings of the GWA studies showing that hypofunctional NRLP3
mutations are associated with Crohn’s disease. We report that loss of NLRP3 was associated
with; 1) reductions in the anti-inflammatory cytokine IL-10 and protective growth factor
TGF-β expression during colitis, 2) underlying functional defects of Nlrp3-deficient
macrophages and neutrophils, 3) dysregulation of β-defensin expression, 4) impaired crypt
bactericidal activity and 5) dramatic alterations in intestinal microbiota. Many of these
changes have also been observed in patients with IBD (62,65-69). These data suggest that a
loss of NLRP3 function confers susceptibility for Crohn’s disease by reducing the
propensity of innate mechanisms to immediately combat mucosal insult by the intestinal
microbiota, resulting in the induction of chronic inflammation. Furthermore, some of the
changes noted in the Nlrp3-/- mice have been described with the hypofunction mutations of
NOD2 that are associated with Crohn’s disease. These studies further support the hypothesis
that innate immune signaling by NLRs (including both NLRP3 and NOD2) play critical
roles regulation of intestinal inflammation and maintenance of intestinal homeostasis.
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Abbreviations
CD Crohn’s disease
UC ulcerative colitis
DSS dextran sulphate sodium
TNBS 2,4,6-trinitrobenzenesulfonic acid
WT wild-type
NLR nucleotide binding domain leucine-rich-repeat gene-containing
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NLRP3 NLR family pyrin domain containing 3
GWA genome wide association
MDP muramyl dipeptide
MSU monosodium urate
CAPS cryopryin-associated periodic syndromes
BM bone-marrow
NOx nitrate/nitrite
MPO myeloperoxidase
H&E hematoxylin and eosin
TRFLP terminal restriction fragment polymorphism
OPL-S Orthogonal-projection to latent structure
MBD mouse β-defensin
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Figure 1.
Nlrp3−/− mice exhibit enhanced susceptibility to DSS-induced colitis as exhibited by
accelerated weight loss (A); reduced hematocrit (B); increased colonic MPO (C). Nlrp3−/−
mice exposed to DSS exhibited significantly more inflammation, elevated damage score and
overall magnitude of ulceration (D-E; Inflammation score ×10), which is evident in colonic
sections stained with H&E. N=8-12; * denotes p<0.05 compared to WT mice; ** denotes
p<0.005 compared to WT mice.
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Figure 2.
Nlrp3−/− mice exhibit enhanced susceptibility to TNBS-induced colitis as exhibited by
accelerated weight loss (A) and increased colonic MPO (B). Nlrp3−/− mice exposed to
TNBS exhibited significantly more inflammation and elevated damage which is evident in
colonic sections stained with H&E (C) and quantified by blinded histological assessment
(D). N=8/group; * denotes p<0.05 compared to WT mice.
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Figure 3.
Cytokine, chemokine and NOx levels are altered in Nlrp3−/− mice exposed to a 7-day course
of DSS colitis when compared to WT mice. N=3-8/group; * denotes p<0.05 compared to
levels observed in WT mice.
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Figure 4.
Peritoneal macrophages isolated from Nlrp3-/- mice fail to respond to bacterial muramyl
dipeptide (A) Macrophages pre-treated with ultra-pure lipopolysaccharide (LPS, 10ng/mL
for 1h) exhibit IL-1β processing and release into culture media when exposed (6h) to
muramyl dipeptide (MDP, 10μg/mL), monosodium urate crystals (MSU, 50μg/mL),
aluminum adjuvant (Alum, 500μg/mL) and adenosine triphospate (ATP, 5mM). IL-1β
processing is inhibited by glyburide (100μM), a selective inhibitor of the NLRP3-
inflammasome, and absent in NLRP3-deficient macrophages (B). Western blot are
representative of 4 separate experiments.
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Figure 5.
Chemotaxis and spontaneous apoptosis are altered in BM-derived neutrophils isolated from
Nlrp3−/− mice. (A) Overall neutrophil movement in response to PBS (vehicle control), KC
(1.25 μM), leukotriene B4 (1 μM), WKTMVm (1 μM) and C5a (1 μM) as assessed with an
under-agarose assay. (B) Neutrophil chemotaxis expressed as the number of cells that
migrated towards the chemoattractant as a percentage of the total number of cells that
moved in any direction. N=4; * denotes p<0.05 compared to WT cells. (C) Spontaneous
apoptosis of BM-derived neutrophils after 12h in culture as assessed by flow cytometry.
N=4; * denotes p<0.05 compared to WT cells. (D-E) Assessment of PMA(8 μM; D)- and
fMLP(8 mM; E)-induced superoxide production in BM-derived neutrophils isolated from
WT and Nlrp3−/− mice. N=4, * denotes p<0.05 compared to WT cells. Addition of
superoxide dismutase (SOD, 1500 U) was employed as a control to quench superoxide
accumulation (D).
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Figure 6.
Nlrp3−/− mice display altered expression of β-defensin transcripts and exhibit a unique
intestinal microbiota. (A) qPCR assessment of β-defensin transcripts in naïve WT and
Nlrp3−/− mice expressed as a fold-change. (B) qPCR assessment of β-defensin transcripts in
DSS-treated WT and Nlrp3−/− mice expressed as a fold-change (7-day course of 2.5%
DSS). defb1–mouse β-defensin 1; defb2–mouse β-defensin 2; defb3–mouse β-defensin 3;
defb4–mouse β-defensin 4. * denotes p<0.05 compared to naïve WT mice; N=5/group. (C)
The antimicrobial capacity of crypt secretions derived from WT and Nlrp3−/− mice.
Overnight colony growth in secretion-treated E. coli cultures was compared to untreated
cultures and expressed as percent reduction in colony numbers, termed percent killing. *
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denotes p<0.05 compared to WT mice; N=3. (D) Supervised OPL-S discriminant analysis of
TRFLP binary data shows that naïve Nlrp3−/− mice display a unique microbiota when
compared to WT littermates. (E) Several unique TRFs were found to significantly
distinguish the two groups. N=7/group for TRFLP analysis.
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